One-way sensitivity analysis was performed to assess the effects of the different model parameters on the cost effectiveness of PPI co-medication. They are shown in tornado diagrams for the effect of parameter values of the 5th and 95th percentiles on the net monetary benefit (NMB). The incremental NMB shows the difference between PPI co-medication and no PPI use in LDASA users at risk as a monetary value. This was calculated as the maximum amount an individual is willing to pay for a unit or effect (QALY), the so-called willingness to pay (WTP), minus the difference in costs of both strategies [32]. The WTP assumed here was €30,000, as an example, to showcase the influences of the parameters.
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.